Valeant Pharmaceuticals: Intrigued...Really?

Rodman & Renshaw's price objective points to a potential upside of 26.21% from the stock's previous close.

Several other brokerages have also recently weighed in on VRX. Jefferies maintained it with "Buy" rating and $42 target in Friday, December 9 report. The firm earned "Market Perform" rating on Thursday, May 11 by BMO Capital Markets. 5,000 Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares with value of $73,650 were bought by Ross Thomas W. Sr. During the last month, the stock has changed -2.23% and performed -24.76% over the last 6 months. The Company dividend yield observed at 4.49%. The firm has a 50 day moving average price of $10.15 and a 200-day moving average price of $14.01. Taking a wider view, the current separation from the 52-week high is -5.65%, and the distance from the 52-week low is presently 13.78%. Twin Tree Mgmt Ltd Partnership holds 0% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 5,100 shares.

The ETF's YTD performance is 0%, the 1 year is 0% and the 3 year is 0%. Valeant Pharmaceuticals Intl had a negative net margin of 22.17% and a positive return on equity of 43.81%. Analyst's mean target price for CYTR is $4.00 while analysts mean recommendation is 2.00. The Phoenix Investment Adviser Llc holds 1,000 shares with $35,000 value, down from 93,900 last quarter. During the same quarter in the prior year, the firm earned $1.55 earnings per share. Equities analysts expect that Valeant Pharmaceuticals Intl will post $3.89 earnings per share for the current year. If you are accessing this piece of content on another domain, it was stolen and republished in violation of global copyright & trademark legislation. If you are reading this piece on another domain, it was illegally copied and reposted in violation of USA and worldwide copyright and trademark laws.

Now the shares of Valeant Pharmaceuticals International, Inc. The rating was maintained by BTIG Research on Thursday, May 11 with "Neutral". The shares were bought at an average cost of $13.90 per share, for a total transaction of $278,000.00. Market Capitalization if basically the market value of the company's shares outstanding. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Wells Fargo & Co reiterated an "underperform" rating on shares of Valeant Pharmaceuticals Intl in a report on Thursday, February 16th. Kistler invested in 0.02% or 3,339 shares. Moreover, Gramercy Funds Management Llc has 1.47% invested in the company for 168,141 shares. The disclosure for this purchase can be found here. The company has dropped -4.72% in past 3 months and in the last five trades has moved down -1.27%. Maybe the focus is on finding a stock that has recently taken a turn for the worse for no real apparent reason. Finally, Morgan Stanley boosted its position in shares of Valeant Pharmaceuticals Intl by 241.6% in the third quarter. Fosun International Ltd now owns 303,708 shares of the specialty pharmaceutical company's stock worth $7,456,000 after buying an additional 36,738 shares during the period. Aperio Grp Ltd Llc invested 0% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). ValueAct Holdings - L.P. bought $32.47 million worth of stock. On Friday, August 14 the stock rating was maintained by Jefferies with "Buy". Also, Director Schutter Richard U. De purchased 10,000 shares of the stock in a transaction dated Wednesday, March 15th.

Multiple company employees have indulged in significant insider trading.

Paulson & Co. Inc. owns $272.93 million in Valeant Pharmaceuticals International, Inc., which represents roughly 5.84% of the company's market cap and approximately 10.86% of the institutional ownership. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Latest News